Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC

      00:00 - 00:00  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

  • +

    P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC

      00:00 - 00:00  |  Presenter: Ying Cheng

      • Abstract

      Loading...

  • +

    PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 06:30 - 08:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

      06:47 - 06:57  |  Presenter: Luis Paz-Ares

      • Abstract

      Loading...

  • +

    OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

      09:30 - 09:40  |  Presenter: David Carbone

      • Abstract

      Loading...

  • +

    PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 14:30 - 16:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02A.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

      14:47 - 14:57  |  Presenter: Luis Paz-Ares

      • Abstract

      Loading...

  • +

    IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

    • 16:15 - 17:15
    • 9/13/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS14.01 - Disease Landscape Overview

      16:15 - 16:30  |  Presenter: Luis Paz-Ares

      • Abstract

      No abstract available for this presentation

  • +

    MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA14.02 - RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

      18:50 - 18:55  |  Presenter: Fernando Lopez-Rios

      • Abstract

      Loading...

  • +

    MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies

    • 20:00 - 21:00
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Small Cell Lung Cancer/ NET
    • +

      MA16.01 - Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer

      20:00 - 20:05  |  Presenter: Vivek Subbiah

      • Abstract

      Loading...

    • +

      MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

      20:30 - 20:35  |  Presenter: Marina Chiara Garassino

      • Abstract

      Loading...